


# Antibody-drug conjugate publication spotlight: our top three recent peer-reviewed journal articles featuring Fortrea oncologists discussing ADC drug development

Antibody-drug conjugates (ADCs) represent one of the largest growth segments in oncology, holding the promise of more effective therapies that can offer lower systemic toxicity, for better patient outcomes. With more than a dozen ADCs having received FDA approval so far, and approximately 200 more in the drug development pipeline, the global market for ADCs has topped \$10B in recent years and is forecasted to continue to grow as this class of drugs develops and is applied to more clinical indications.

Fortrea supports our sponsors with a team of 60 oncologists who employ a collaborative approach, which can result in co-authorship of peer reviewed journal articles based on projects we've supported. In addition, they have contributed to industry knowledge via articles about their own academic and collaborative work. We are proud that our oncology team contributes to the advancement of cancer research in this way. Some of our latest publications relating to ADCs include the following articles.



## 1 “Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.”

*Cancer Treatment and Research Communications*.  
April 2023.

Antibody-drug conjugates have emerged as one of the most exciting advances in cancer therapeutics in the past decade, and Fortrea has been involved in the execution of clinical trials for many such molecules. In this manuscript, we highlight the growing role of ADCs in non-small cell lung cancer. Read the article here: <https://www.sciencedirect.com/science/article/pii/S24682942233000345>

2 “Is HER2-low a new clinical entity or merely a biomarker for an antibody drug conjugate?”

*Oncology & Therapy.*  
November 2023.

Fortrea oncologists make a nuanced analysis of the move from the conventional bimodal HER2 receptor status (HER2-positive and HER2-negative) to a trimodal by adding a new category of HER2-low. Read the article here: <https://doi.org/10.1007/s40487-023-00249-0>

3 “Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics”

*Expert Opinion in Biologic Therapy.*  
June 2021.

In the recent years, breast cancer systemic therapy has been revolutionized by immunotherapy as well as ADCs targeting HER2, TROP2 and other targets. Read the article here: <https://doi.org/10.1080/14712598.2021.1936494>



See a full list of Fortrea oncology publications starting in 2020.

Fortrea  
Together, exceptional is possible

 **LEARN MORE** at [fortrea.com/oncology](https://fortrea.com/oncology)

